Raymond Perez Email & Phone Number

Paris, France, Fr

• Portfolio: Immunomodulatory agents (including CPI, targeted cytokines, ADCs, mRNA, T/NK cell engagers (solid tumors), NK cell therapeutics (solid tumor), and small molecules).• Accountable for 12 clinical / near-clinical assets, post-candidate selection through the life cycle of projects to date (including conception and execution of development programs, asset/portfolio strategies and prioritization, internal and external messaging, Governance, and cross-functional interface with all key stakeholders.• All milestones achieved on or ahead of timelines, including 2 assets where totality of data was efficiently leveraged for Go/No Go decision > 6 months earlier than targeted.• Line manager for 8 direct reports (Project Leads/ Clinical Study Directors).• Key contributor to above-asset and cross-TA strategic planning.• Patents: 2 pending (non-public).

Lawrence Township, Nj, Us

• Clinical Trial Physician, accountable for 5 current programs/assets as senior clinician including: (1) initial or revised clinical / translational strategies ; (2) preclinical to human transition; and (3) execution and data analyses for clinical trials. Led teams that delivered IND, site selection/activation, and FPFV for 3 FIH programs in 2020-21.* Business development: - Clinical SME for technical diligence of novel clinical-stage asset/program, supporting negotiation and ultimate acquisition. - Post-acquisition, led multifunctional R&D Integration team that delivered: (1) intake of all preclinical, clinical, safety, pharmacokinetic, and pharmacodynamic data; (2) authoring of multiple CSRs; regulatory transition, including assumption of active INDs; (3) maintenance of relationships with investigators; and, (4) initial clinical protocol and clinical development plans and execution for asset/program • Represent BMS on ASCO ad-hoc workgroups; current focus on Broadening Clinical Trials Eligibility. Co-led steering committee that delivered one, and contributed to 5 additional, peer-reviewed publications in 2021, as well as a webinar in April 2021.

Lawrence Township, Nj, Us

• Senior Clinical representative to two different (sequentially) Early Development Teams (EDTs), directly accountable for strategy and trial execution of 6 FIH clinical assets and preclinical to human transition for 4 additional assets; plus, oversight of clinical studies led by direct reports, and indirect accountability for 7 additional clinical assets.• Line manager for Asset Leads (MD/MM) and Senior Asset Leads (Senior MD/MM);accountable for hiring, mentoring and development of 8 direct reports (up to 6 concurrent).• Represented BMS on external policy projects through the ASCO CRC and ad-hoc workgroups. Led Expedited IND Safety Reporting project, resulting in 2 peer-reviewed publications.• Co-led Early Oncology Writing Seminar, a multi-part cross-functionaleducational program targeting ECLs/SECLs. Aim was improved writing skills for protocols, IBs,regulatory communications, and CSRs. Delivered didactic educational materials, reference resources, hands-on activities, and video content for 7 ~ monthly sessions; result was improved clarity and efficiency of authoring of in-scope documents across the Department.• Patents: co-inventor; 4 provisional US and international.

Lawrence Township, Nj, Us

• Led execution of clinical studies and data interpretation for CD73 inhibitor program. Clinical lead for team that completed dose titration, devised expansion strategy, implemented prospective biomarker-based patient selection, and managed first public disclosure.• Clinical lead for multifunctional matrix team supporting preclinical to human transition and initial clinical development of new asset, including initial clinical development and translational medicine plans.• Provided medical and scientific expert advice to discovery and due diligence teams, contributing to compound selection and clinical development planning (multiple assets).

Kansas City, Ks, Us

I led the KU Cancer Center Early Phase trials effort, as Chair of the Early Phase Clinical Trials Disease Working Group and as an active principal investigator on over 30 early phase trials. I also ran a basic science laboratory focused on novel therapies targeting signaling modulated by SPRY proteins. I held several leadership positions at the KU Cancer Center, including Medical Director of the Clinical Trials Office and co-leader of the Drug Discovery, Development, and Experimental Therapeutics Research Program; I also led the subcommittee that defined scientific and research initiatives for the Cancer Center's 2012-2017 strategic plan. In addition, I was the inaugural Medical Director of the KU Clinical Research Center (CRC), a freestanding 82,400 square foot facility housing a dedicated Phase I Oncology unit, GLP-compliant bioanalytical facility, NIH/NCATS CTSA-funded Clinical Translational Science Unit (CTSU; previously General Clinical Research Center, or GCRC), NIH Alzheimer's center, regional oncology education and research network, and associated research support staff. Under my leadership, patient visits to the oncology early phase unit grew by an annual average of 42%, from 2012-2015.

I developed Dartmouth's Phase I clinical trials program with Lionel Lewis, M.D., and we were responsible for more than doubling early-phase trials accrual. I also held several leadership positions in the Norris Cotton Cancer Center, including co-Director of the Molecular Therapeutics Research Program, Associate Director for Clinical Research, Medical Director of the Clinical Research Office, and Chair of the institutional Safety and Data Monitoring Committee. I was a core faculty member for an ABCP-accredited fellowship in clinical pharmacology (Director, Dr. Lewis). Finally, I was responsible for mentoring several graduate students, residents, fellows, and junior faculty.

Buffalo, Ny, Us

I was an active clinical investigator in the Phase I Oncology group, and also led the multidisciplinary Soft-tissue malignancies clinic (Melanoma/Sarcoma). I was a key contributor to the team that successfully competed for a NCI Phase I U-01 contract. I also ran a basic laboratory, focused on cellular/molecular determinants of sensitivity to platinum anticancer drugs, and mentored undergraduate/graduate students, residents, and oncology fellows in both clinical and laboratory settings.

Medical Oncology Research Fellowship

Internal Medicine Residency

Doctor Of Medicine (M.D.), Medicine

Bachelor Of Science (B.S.), Integrated Life Sciences